Obalon Engages Helmuth T. Billy, MD as Medical Director for its First Company-Owned Weight Loss Treatment Center
September 03 2019 - 9:00AM
Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based company
focused on commercializing the Obalon Balloon System, the first and
only FDA-approved swallowable, gas-filled intra-gastric balloon for
weight loss announces that it has engaged Helmuth T. Billy,
MD, as Medical Director to oversee medical affairs for the
Company’s first weight loss treatment center. Located in San
Diego’s North County area, the 2,000 square foot Obalon Center for
Weight Loss is expected to begin treating patients in the fall of
2019.
“Dr. Billy is an internationally renowned bariatric surgeon
based in Southern California. We are very pleased to engage him as
Medical Director for our first planned Obalon Center for Weight
Loss,” said William J. Plovanic, Obalon’s President and Chief
Financial Officer. “Known throughout the bariatric surgery field,
Dr. Billy is a perfect fit to oversee the medical aspects of our
treatment center strategy, as we strive to continue building
Obalon’s retail brand and reputation for providing a high quality
and effective solution for patients seeking to lose weight when
diet and exercise are not enough and surgery is not desired or
recommended.”
“There are many individuals struggling to lose weight and
improve their health and appearance. Many people do not want or do
not qualify for traditional surgical options,” said Dr. Billy. “The
Obalon Center for Weight Loss in San Diego is intended to make it
easier for those patients to access non-surgical weight loss
options. The Obalon Balloon System is an innovative technology that
has proven to be safe and effective in rigorous clinical trials and
commercial settings. I am excited to oversee medical affairs at the
Company’s first facility to bring Obalon’s solution to the
community.”
Dr. Helmuth Billy is currently Director of Bariatric Surgery at
St. John's Regional Medical Center, a bariatric Center of
Excellence and recognized by the American College of Surgeons
(MBSAQIP), Blue Cross, Blue Shield and Health Net as an accredited
Bariatric program. In addition, he has extensive international
experience and is a visiting consultant for the General
Surgery/Bariatric Surgery program at Hamad Medical Corporation in
Doha, Qatar, one of the largest international Obalon Balloon System
treatment programs outside the United States. He also serves as the
Medical Director of the Community Memorial Hospital, an American
College of Surgeons accredited Bariatric Center located in Ventura,
California. Dr. Billy has educated and proctored numerous surgeons
as part of their educational training and has been an invited
faculty member at national educational events and surgeon training
workshops. He has been a featured speaker at National meetings and
International Congresses with subsequent contribution to U.S.
Guidelines on the treatment and management of obesity.
Additionally, he has participated or been responsible for
overseeing multiple clinical studies used to demonstrate to the FDA
the safety and effectiveness of various surgical and non-surgical
medical devices for weight loss, including the U.S. clinical
studies that supported FDA-approval of the Obalon Balloon
System. Dr. Billy is a former Commander of the U.S. Naval
Reserves and obtained his undergraduate degree in Molecular Biology
at the University of California, Berkeley and Medical Degree at the
University of California, Davis School of Medicine.
About Obalon Therapeutics, Inc. Obalon
Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company
focused on developing and commercializing novel technologies for
weight loss. For more information, please
visit www.obalon.com.
Forward-Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Obalon Therapeutics, they are forward-looking statements reflecting
the current beliefs and expectations of management made pursuant to
the safe harbor of the Private Securities Reform Act of 1995. Such
forward-looking statements involve substantial risks and
uncertainties that could cause Obalon Therapeutics' future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Obalon
Therapeutics undertakes no obligation to update or revise any
forward-looking statements. For a description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Obalon Therapeutics' business in general, please refer
to Obalon Therapeutics’ annual report on Form 10-K filed with the
Securities and Exchange Commission on February 22, 2019, Form 10-Q
filed with the Securities and Exchange Commission on July 24, 2019,
and its future periodic reports filed with the Securities and
Exchange Commission.
For Obalon Therapeutics, Inc.
Investor Contact: William Plovanic President & Chief
Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103
wplovanic@obalon.com
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Apr 2023 to Apr 2024